Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families
- PMID: 10389909
Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families
Abstract
Positive family history is a significant risk factor for prostate cancer. Improved knowledge of the epidemiology and molecular basis of hereditary prostate cancer has led to a need for counseling and clinical follow-up for men with a positive family history of prostate cancer. However, very little information is available on the efficacy of early screening procedures, such as serum prostate-specific antigen (PSA) measurements, in the management of genetically predisposed, high-risk individuals. In a nationwide study, we obtained family histories from 2099 Finnish prostate cancer patients and identified 302 families with two or more affected cases. Here, 209 asymptomatic 45-75-year-old males from these families were included in a study to determine the frequency of serum PSA positivity and the prevalence of subclinical prostate cancers. Serum PSA was elevated in 21 (10.0%) of these high-risk individuals. Seven prostate cancers (3.3%) and two high-grade prostatic intraepithelial neoplasia lesions were diagnosed, with three cancers occurring in men ages < or = 59 years. Men from prostate cancer families with an average age of onset of < 60 years had a significantly higher frequency of PSA positivity (28.6%, P = 0.01) as well as cancers (14.3%, P = 0.02) than those with a later age of onset. The results suggest that prostate cancer development in genetically predisposed individuals is preceded by a subclinical period when PSA detection is possible. Serum PSA screening may be particularly useful in men with a family history of early-onset prostate cancer.
Similar articles
-
Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).Urology. 2005 Feb;65(2):343-6. doi: 10.1016/j.urology.2004.09.046. Urology. 2005. PMID: 15708050
-
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).Urology. 2004 Feb;63(2):309-13; discussion 313-5. doi: 10.1016/j.urology.2003.09.083. Urology. 2004. PMID: 14972478
-
Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.Urology. 2004 Feb;63(2):316-20. doi: 10.1016/j.urology.2003.09.028. Urology. 2004. PMID: 14972481
-
Prognostic value of serum markers for prostate cancer.Scand J Urol Nephrol Suppl. 2005 May;(216):64-81. doi: 10.1080/03008880510030941. Scand J Urol Nephrol Suppl. 2005. PMID: 16019759 Review.
-
Prostate-specific antigen kinetics in localized and advanced prostate cancer.BJU Int. 2009 Mar;103(5):578-87. doi: 10.1111/j.1464-410X.2009.08345.x. Epub 2009 Feb 6. BJU Int. 2009. PMID: 19210674 Review.
Cited by
-
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.Eur Urol. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15. Eur Urol. 2014. PMID: 24484606 Free PMC article.
-
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.BJU Int. 2011 Jan;107(1):28-39. doi: 10.1111/j.1464-410X.2010.09648.x. Epub 2010 Sep 14. BJU Int. 2011. PMID: 20840664 Free PMC article.
-
The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk.Br J Cancer. 2006 Feb 27;94(4):499-506. doi: 10.1038/sj.bjc.6602925. Br J Cancer. 2006. PMID: 16434997 Free PMC article.
-
Genetic susceptibility to prostate cancer: a review.Fam Cancer. 2003;2(1):57-67. doi: 10.1023/a:1023299520828. Fam Cancer. 2003. PMID: 14574167 Review.
-
Inherited predisposition to prostate cancer.Eur J Epidemiol. 2003;18(11):1027-36. doi: 10.1023/a:1026101914592. Eur J Epidemiol. 2003. PMID: 14620936 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Research Materials
Miscellaneous